Latest Period
Q1 2026
Security Snapshot
UNITED THERAPEUTICS Corp - Common Stock (UTHR) Institutional Ownership
CUSIP: 91307C102
13F Institutional Holders and Ownership History from Q1 2014 to Q2 2026
Institutions Reporting
849
Shares (Excl. Options)
41,496,787
Price
$592.98
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock
- Symbol
- UTHR on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 41,496,787
- Total 13F value
- $24,568,793,524
- Portfolio coverage rank
- 0.03%
- Share change
- -250,257
- Value change
- -$39,647,493
- Number of holders
- 849
- Shares outstanding
- 43,898,805
- SEC-reported price per share
- $541.83
- Insider filing price
- $541.83
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- UTHR - UNITED THERAPEUTICS Corp - Common Stock is tracked under CUSIP 91307C102.
- 849 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 849 to 29 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $24,568,793,524 to $102,670,154.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 849 institutions filings for Q1 2026.
Security key
91307C102
Latest holder period
Q1 2026
13F holders
849
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
UTHR full holder history
UNITED THERAPEUTICS Corp SEC filings
UNITED THERAPEUTICS Corp company facts
UNITED THERAPEUTICS Corp insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 91307C102:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
UTHR
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP | 5.7% | +24% | $1,189,616,977 | +$202,245,781 | 2,441,492 | +20% | Wellington Management Group LLP | 31 Dec 2025 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.2% | $1,351,014,797 | 2,278,348 | Vanguard Capital Management | 31 Mar 2026 | |||
| STATE STREET CORP | 4.9% | $661,670,195 | 2,199,994 | STATE STREET CORPORATION | 31 Dec 2024 |
As of 31 Mar 2026, 849 institutional investors reported holding 41,496,787 shares of UNITED THERAPEUTICS Corp - Common Stock (UTHR). This represents 95% of the company’s total 43,898,805 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
62%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| BlackRock, Inc. | 12% | 5,399,649 | +4.4% | 0.06% | $3,201,883,611 |
| Avoro Capital Advisors LLC | 6% | 2,630,000 | +0.92% | 15% | $1,559,537,400 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.2% | 2,264,247 | -7.3% | 0.25% | $1,342,653,186 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.6% | 2,003,742 | 0% | 0.06% | $1,188,178,931 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.5% | 1,957,539 | 0% | 0.03% | $1,160,781,476 |
| STATE STREET CORP | 4.2% | 1,843,963 | +0.08% | 0.04% | $1,093,433,180 |
| RENAISSANCE TECHNOLOGIES LLC | 4.1% | 1,787,019 | -6.4% | 1.7% | $1,059,666,527 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.8% | 1,233,029 | +3.3% | 0.05% | $729,920,363 |
| JANUS HENDERSON GROUP PLC | 2% | 866,930 | +8.9% | 0.25% | $514,015,988 |
| AQR CAPITAL MANAGEMENT LLC | 1.9% | 826,226 | -36% | 0.22% | $486,424,477 |
| ASSETMARK, INC | 1.4% | 616,050 | -3% | 0.74% | $365,305,135 |
| Invesco Ltd. | 1.4% | 608,367 | -0.06% | 0.06% | $360,749,465 |
| FMR LLC | 1.2% | 528,346 | +31% | 0.02% | $313,298,624 |
| DIMENSIONAL FUND ADVISORS LP | 1.2% | 512,739 | -2.9% | 0.06% | $304,029,148 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 1% | 457,000 | +7.3% | 3.2% | $270,991,860 |
| NORTHERN TRUST CORP | 0.99% | 436,566 | +4.3% | 0.03% | $258,874,907 |
| BAILLIE GIFFORD & CO | 0.98% | 428,127 | +33% | 0.26% | $253,870,748 |
| MORGAN STANLEY | 0.93% | 409,287 | +5.1% | 0.01% | $242,699,647 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 0.92% | 405,447 | +15% | 0.03% | $240,423,000 |
| LSV ASSET MANAGEMENT | 0.91% | 398,665 | -2.3% | 0.51% | $236,400,000 |
| CITADEL ADVISORS LLC | 0.82% | 360,643 | +93% | 0.15% | $213,854,086 |
| Caisse de depot et placement du Quebec | 0.78% | 343,659 | +16% | 0.33% | $203,782,914 |
| Bank of New York Mellon Corp | 0.75% | 329,148 | -1.3% | 0.04% | $195,178,326 |
| Swedbank AB | 0.75% | 327,122 | +0.72% | 0.2% | $193,976,805 |
| Pictet Asset Management Holding SA | 0.7% | 309,220 | +0.78% | 0.19% | $183,306,233 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
50
Latest
Q1 2026
Rows shown
1-25 of 50
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 189,473 | $102,670,154 | +$20,137,057 | $541.83 | 29 |
| 2026 Q1 | 41,496,787 | $24,568,793,524 | -$39,647,493 | $592.98 | 849 |
| 2025 Q4 | 41,674,368 | $20,284,637,524 | +$459,092,354 | $487.25 | 832 |
| 2025 Q3 | 40,884,780 | $17,141,521,441 | -$1,065,484,238 | $419.21 | 701 |
| 2025 Q2 | 43,924,518 | $12,621,620,981 | -$132,393,705 | $287.35 | 662 |
| 2025 Q1 | 44,441,020 | $13,691,236,526 | +$58,445,640 | $308.27 | 661 |
| 2024 Q4 | 43,992,356 | $15,526,430,783 | +$60,965,879 | $352.84 | 667 |
| 2024 Q3 | 43,520,361 | $15,594,079,368 | -$719,584,018 | $358.35 | 617 |
| 2024 Q2 | 45,751,455 | $14,568,456,882 | +$331,436,428 | $318.55 | 557 |
| 2024 Q1 | 45,081,525 | $10,361,695,587 | +$141,369,039 | $229.72 | 518 |
| 2023 Q4 | 44,516,671 | $9,786,687,446 | +$24,490,915 | $219.89 | 528 |
| 2023 Q3 | 44,424,001 | $10,034,347,626 | -$137,617,629 | $225.87 | 503 |
| 2023 Q2 | 44,929,853 | $9,916,555,660 | -$53,987,464 | $220.75 | 466 |
| 2023 Q1 | 45,106,269 | $10,099,164,591 | -$14,220,192 | $223.96 | 499 |
| 2022 Q4 | 44,906,712 | $12,485,251,712 | +$52,130,518 | $278.09 | 506 |
| 2022 Q3 | 44,754,285 | $9,370,900,072 | +$62,537,202 | $209.38 | 450 |
| 2022 Q2 | 44,045,171 | $10,378,944,055 | +$127,464,630 | $235.64 | 462 |
| 2022 Q1 | 44,003,492 | $7,893,754,591 | +$134,402,123 | $179.41 | 416 |
| 2021 Q4 | 43,119,761 | $9,315,950,531 | -$262,053,365 | $216.08 | 409 |
| 2021 Q3 | 44,131,602 | $8,148,234,087 | +$112,030,536 | $184.58 | 415 |
| 2021 Q2 | 43,453,740 | $7,794,694,945 | +$9,014,738 | $179.41 | 397 |
| 2021 Q1 | 43,411,843 | $7,268,500,823 | +$26,763,473 | $167.27 | 384 |
| 2020 Q4 | 43,003,015 | $6,528,125,218 | +$196,460,628 | $151.79 | 347 |
| 2020 Q3 | 41,894,495 | $4,231,829,902 | -$29,144,918 | $101.00 | 320 |
| 2020 Q2 | 42,050,372 | $5,086,767,081 | -$63,243,154 | $121.00 | 338 |